ArticleBMC genomics2014
Phylum-wide comparative genomics unravel the diversity of secondary metabolism in Cyanobacteria.
Article in BMC genomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 170 citations in OpenAlex.
- AssessingJournal of fungi (Basel, Switzerland) · 2026Article
- AI-Accelerated Structure Elucidation of Boavistamides A-C, Cyclic Depsipeptides from a Marine Filamentous Cyanobacterium Collected in Cabo Verde.bioRxiv : the preprint server for biology · 2026Article
- Multi-Omic Assessment of Microbial Communities and Their Polyketide Biosynthetic Potential Across Abyssal Sediments.Environmental microbiology · 2026Article
- Multichassis Expression of Cyanobacterial and Other Bacterial Biosynthetic Gene Clusters.ACS synthetic biology · 2025Article
- Secondary Metabolites Predict Diazotrophic Cyanobacteria: A Model-Based Cheminformatic Approach.Metabolites · 2025Article
- Menominin A and B: Cytotoxic Cyclodepsipeptides from the Freshwater Sponge-Associated CyanobacteriumJournal of natural products · 2025Article
- Metatranscriptomics reveals gene expression dynamics during an anatoxin-a producing Dolichospermum bloom in a western coastal lake.Chemosphere · 2025Article
- Marine Cyanobacteria: A Rich Source of Structurally Unique Anti-Infectives for Drug Development.Molecules (Basel, Switzerland) · 2024Review
- Screening of Lipid-Reducing Activity and Cytotoxicity of the Exometabolome from Cyanobacteria.Marine drugs · 2024Article
- Diversity and specificity of molecular functions in cyanobacterial symbionts.Scientific reports · 2024Article
- High Structural Diversity of Aeruginosins in Bloom-Forming Cyanobacteria of the GenusMarine drugs · 2023Article
- Recent Advances in Cyanotoxin Synthesis and Applications: A Comprehensive Review.Microorganisms · 2023Review
- Cyanobacteria: A Promising Source of Antifungal Metabolites.Marine drugs · 2023Review
- Cyanotoxins and Other Bioactive Compounds from the Pasteur Cultures of Cyanobacteria (PCC).Toxins · 2023Review
- Deciphering Chemical Mediators Regulating Specialized Metabolism in a Symbiotic Cyanobacterium.Angewandte Chemie (International ed. in English) · 2022Article
- Cyanobacterial secondary metabolites towards improved commercial significance through multiomics approaches.World journal of microbiology & biotechnology · 2022Review
- Discovery of Anticancer Agents of Diverse Natural Origin.Journal of natural products · 2022Article
- Toxic/Bioactive Peptide Synthesis Genes Rearranged by Insertion Sequence Elements Among the Bloom-Forming CyanobacteriaFrontiers in microbiology · 2022Article
- Article
- Final Destination? PinpointingLife (Basel, Switzerland) · 2021Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCyanobacteria are an ancient lineage of photosynthetic bacteria from which hundreds of natural products have been described, including many notorious toxins but also potent natural products of interest to the pharmaceutical and biotechnological industries. Many of these compounds are the products of non-ribosomal peptide synthetase (NRPS) or polyketide synthase (PKS) pathways. However, current understanding of the diversification of these pathways is largely based on the chemical structure of the bioactive compounds, while the evolutionary forces driving their remarkable chemical diversity are poorly understood.
resultsWe carried out a phylum-wide investigation of genetic diversification of the cyanobacterial NRPS and PKS pathways for the production of bioactive compounds. 452 NRPS and PKS gene clusters were identified from 89 cyanobacterial genomes, revealing a clear burst in late-branching lineages. Our genomic analysis further grouped the clusters into 286 highly diversified cluster families (CF) of pathways. Some CFs appeared vertically inherited, while others presented a more complex evolutionary history. Only a few horizontal gene transfers were evidenced amongst strongly conserved CFs in the phylum, while several others have undergone drastic gene shuffling events, which could result in the observed diversification of the pathways.
conclusionsTherefore, in addition to toxin production, several NRPS and PKS gene clusters are devoted to important cellular processes of these bacteria such as nitrogen fixation and iron uptake. The majority of the biosynthetic clusters identified here have unknown end products, highlighting the power of genome mining for the discovery of new natural products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.